Kari Tanderup, Professor at Aarhus University, shared a post on LinkedIn:
“The first results of the retroCOSMOS study were presented yesterday at ESTRO26.
26 centers collaborated on collecting data from 429 oligometastatic or oligo-recurrent cervical cancer patients.
This multicentre analysis highlighted that patients can experience prolonged survival beyond first progression through repeated local and systemic treatments.”
Other articles featuring Kari Tanderup on OncoDaily.